Skip to main content
. 2021 Feb 2;5(3):725–736. doi: 10.1182/bloodadvances.2020002378

Figure 1.

Figure 1.

Study design, treatment schema, and subgroups. aSC dose adjustments were not permitted. bPer protocol and zoledronic acid label, IV product was dose adjusted for baseline CrCl, and subsequent dose intervals were determined by serum creatinine levels. PBSC, peripheral blood stem cell; Q4W, every 4 weeks; SC, subcutaneous.